Depression among adults with chronic hepatitis C on antiviral treatment in Port-Said, Egypt

  • Samar Mohamed Abbas
  • Hend Mikhail Salama
  • Hebatallah Nour-Eldein
Original Article
  • 14 Downloads

Abstract

Aim

This study aimed to estimate the prevalence of depression among adults with chronic hepatitis C on antiviral treatment.

Subjects and methods

This was a cross-sectional descriptive and analytic study, conducted between January and August 2017, in two centers for hepatitis C virus treatment in Port Said governorate; one center is located in a fever hospital for non-insured persons, and the other is located in Eltadamon, which is a health insurance hospital for insured persons. It included adults with chronic hepatitis C virus infection attending the locations of the study by systematic random sampling of 288 patients. They filled out questionnaires of the Beck Depression Inventory (BDI), socioeconomic status, and medical history.

Results

About one-third (29%) of chronic hepatitis C (CHC) patients had depression varying from mild in 16%, moderate in 6%, and severe depression in 7% of patients. Younger patients were more depressed (p = 0.009); also, females were more depressed than males (p < 0.001), unmarried patients more depressed than married patients (p = 0.014), illiterates more depressed than educated (p = 0.009), not working patients more depressed (p = 0.001), slum residents more depressed (p < 0.001), and finally lower socioeconomic status patients more depressed (p < 0.001). Increased duration of illness associated with depression (p = 0.02), and patients receiving three doses of treatment less depressed (p = 0.01).

Conclusion

Depression is a common problem in CHC patients; they require treatment with both antivirals and antidepressants, and patient continuation of antiviral treatment decreases the prevalence of depression. More education and improvement in socioeconomic status of CHC patients may reduce the prevalence of depression.

Keywords

Depression Chronic hepatitis C Antiviral Hepatitis treatment Adults 

Notes

Acknowledgements

The authors thank all participants for their cooperation.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study protocol was approved by the Research and Ethics Committee of the Faculty of Medicine, Suez Canal University. All procedures performed in the study were in accordance with the 1964 Helsinki Declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. Abdel-Khalek AM (1998) Internal consistency of an Arabic Adaptation of the Beck Depression Inventory in four Arab countries. Psychol Rep 82(1):264–266.  https://doi.org/10.2466/pr0.1998.82.1.264 CrossRefPubMedGoogle Scholar
  2. Beck AT, Sterr R (1984) Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 40:365–367Google Scholar
  3. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J (2002) Relationship of health related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 35(3):704–708.  https://doi.org/10.1053/jhep.2002.31311 CrossRefPubMedGoogle Scholar
  4. Capuron L, Miller A (2004) Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 56(11):819–824.  https://doi.org/10.1016/j.biopsych.2004.02.009 CrossRefPubMedGoogle Scholar
  5. Carta MG, Angst J, Moro MF, Mura G, Hardoy MC, Balestrieri C, Chessa L, Serra G, Lai ME, Farci P (2012) Association of chronic hepatitis C with recurrent brief depression. J Affect Disord 141:361–366.  https://doi.org/10.1016/j.jad.2012.03.020 CrossRefPubMedGoogle Scholar
  6. Dawson B, Trapp RG (2004) Basic & clinical biostatistics, 4th edn. Lange Medical Books/McGraw-Hill, New YorkGoogle Scholar
  7. Dbouk N, Arguedas MR, Sheikh A (2008) Assessment of the PHQ-9 as a screening tool for depression in patients with chronic Hepatitis C. Dig Dis Science 53:1100–1106.  https://doi.org/10.1007/s10620-007-9985-z CrossRefGoogle Scholar
  8. Dwight M, Kowdley K, Russo J, Ciechanowski P, Larson A, Katon W (2000) Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 49(5):311–317.  https://doi.org/10.1016/S0022-3999(00)00155-0 CrossRefPubMedGoogle Scholar
  9. El-Gilany A, El-Wehady A, El-Wasify M (2012) Updating and validation of the socioeconomic status scale for health research in Egypt. East Mediterr Health J 18(9):962–968CrossRefPubMedGoogle Scholar
  10. Elshahawi HH, Hussein MM, Allam EA (2011) Depression comorbidity in patients with chronic hepatitis C and its possible relation to treatment outcome. Middle East Current Psychiatry 18:23–28CrossRefGoogle Scholar
  11. El-Zanaty F, Way A (2009) Egypt demographic and health survey 2008. Ministry of Health, El-Zanaty and Associates, and Macro International, Cairo, 431 pp.Google Scholar
  12. El-Zayadi A (2009) Hepatitis C comorbidities affecting the course and response to therapy. World J Gasteroenterol 15(40):4993–4999CrossRefGoogle Scholar
  13. Gaber M (2014) HCV treatment in Egypt: why cost remains a challenge? Economic and Social Justice Unit, Egyptian Initiative for Personal Rights, CairoGoogle Scholar
  14. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4):1433–1444.  https://doi.org/10.1002/hep.24641 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Golden J, O’Dwyer AM, Conroy R (2005) Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 27:431–438.  https://doi.org/10.1016/j.genhosppsych.2005.06.006 CrossRefPubMedGoogle Scholar
  16. Joo YB, In HK, Seung YS, Young SK, Eun UJ, Junhyeon C (2017) Prevalence and incidence of depression during interferon-based antiviral therapy in chronic Hepatitis C patients in the Republic of Korea. Gut Liver 11(3):426–433CrossRefGoogle Scholar
  17. Lawitz E, Mangia A, Wyles D, Torres MR, Hassanein T, Gordon SC, Schulltz M, Davis MN, Kayali Z, Reddy KR (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878–1887.  https://doi.org/10.1056/NEJMoa1214853 CrossRefPubMedGoogle Scholar
  18. Madhava V, Burgess C, Drucker E (2002) Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2(5):293–302CrossRefPubMedGoogle Scholar
  19. Metwally AM, Elmosalami DM, Salama SI, Abdel Hameed A, Khalifa A, Hemeda SA (2013) Hepatitis C and depression: does Hepatitis C virus chronic patients need psychological support? J Appl Sci Res 9(1):489–497Google Scholar
  20. Michaeel NL, Khalil FA, El Nemr NA, Soliman NM (2014) Assessment of health related quality of life and depression among chronic Hepatitis C patients treated with combined pegylated interferon and ribavirin therapy in the Center of Hepatitis C Virus Treatment in Ismailia. Masters degree thesis, Faculty of Medicine, Suez Canal UniversityGoogle Scholar
  21. Ministry of Health and Population/Egypt, El-Zanaty and Associates/Egypt and ICF International (2015) Egypt health issues survey 2015. Ministry of Health and Population/Egypt and ICF International, Cairo, EgyptGoogle Scholar
  22. Myrela OM, Giovanni O, Beatrice B, Cristiano AK, Michael M, Marco S (2016) Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: a critical systematic review. J Affect Disord 209.  https://doi.org/10.1016/j.jad.2016.11.039
  23. Onyekwere CA, Hameed L (2015) Hepatitis B and C virus prevalence and association with demographics: report of population screening in Nigeria. Trop Doctor 45(4):231–235.  https://doi.org/10.1177/0049475514560211 CrossRefGoogle Scholar
  24. Pawlowski T, Radkowski M, Malyszczak K, Inglot M, Zalewska M, Jablonska J (2014) Depression and neuroticism in patients with chronic hepatitis C: correlation with peripheral blood mononuclear cells activation. J Clin Virol 60(2):105–111CrossRefPubMedGoogle Scholar
  25. Qureshi MO, Khokhar N, Shafqat F (2012) Severity of depression in hepatitis B and hepatitis c patients. J College Phys Surg Pakistan 22(10):632–634Google Scholar
  26. Ridruejo E (2014) Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opin Drug Saf 13(3):307–319.  https://doi.org/10.1517/14740338.2014.884068 CrossRefPubMedGoogle Scholar
  27. Riou J, Aït Ahmed M, Blake A, Vozlinsky S, Brichler S, Eholie S, Boelle PY, Fontanet A (2016) Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepatitis 23:244–255.  https://doi.org/10.1111/jvh.12481 CrossRefGoogle Scholar
  28. Thein HH, Dore GJ (2010) Cognitive function, mood and health-related quality of life in Hepatitis C virus-infected individuals. In: Preedy VR, Watson RR (eds) Handbook of disease burdens and quality of life measures. Springer, New York, NY.  https://doi.org/10.1007/978-0-387-78665-0_191 Google Scholar
  29. Trembling PM, Tanwar S, Dusheiko GM (2012) Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. Expert Rev Anti-Infect Therapy 10(3):269–279CrossRefGoogle Scholar
  30. Tüzün H, Aycan S, İlhan MN (2015) Impact of comorbidity and socioeconomic status on quality of life in patients with chronic diseases who attend primary health care centers. Cent Eur J Public Health 23(3):188–194.  https://doi.org/10.21101/cejph.a3990 CrossRefPubMedGoogle Scholar
  31. Velosa J, Serejo F, Ramalho F, Marinho R, Rodrigues B, Baldaia C, Raimundo M, Ferreira P (2014) A practical guide for antiviral therapy of chronic Hepatitis C. GE Portuguese J Gastroenterol 21(6):221–230.  https://doi.org/10.1016/j.jpge.2014.09.001 CrossRefGoogle Scholar
  32. World Health Organization (2014) Guidelines for the screening, care and treatment of persons with hepatitis C infection. World Health Organization, GenevaGoogle Scholar
  33. World Health Organization (2016) Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016. World Health Organization, Geneva.Google Scholar
  34. Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Godon SC (2014) The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Therapy 39(5):518–531.  https://doi.org/10.1111/apt.12625 CrossRefGoogle Scholar
  35. Younossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, Hezode C, Nader F, Henry L, Hunt S (2016) Sofosbuvir-velpatasvir improves patient-reported outcomes in HCV patients: results from Astral-1 placebo-controlled trial. J Hepatol 65(1):33–39CrossRefPubMedGoogle Scholar
  36. Youssef NF, El Kassas M, Farag A, Shepherd A (2017) Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt. BMC Gastroenterol 17:18.  https://doi.org/10.1186/s12876-017-0581-1 CrossRefPubMedPubMedCentralGoogle Scholar
  37. Zickmund SL, Bryce CL, Blasiole JA, Shinkunas L, LaBrecque DR, Arnold RM (2006) Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. Eur J Gastroenterol Hepatol 18:381–388CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Samar Mohamed Abbas
    • 1
  • Hend Mikhail Salama
    • 1
  • Hebatallah Nour-Eldein
    • 1
  1. 1.Department of Family Medicine, Faculty of MedicineSuez Canal UniversityIsmailiaEgypt

Personalised recommendations